期刊文献+

成人郎格汉斯细胞组织细胞增生症1例报告及文献复习

Adult Langerhans cell histiocytosis:A case report and literature review
下载PDF
导出
摘要 目的:探讨郎格汉斯细胞组织细胞增生症(LCH)的临床和病理特征,为其诊治提供参考。方法:回顾性分析1例LCH患者的临床表现,结合皮肤组织病理检查、影像学检查及随访资料,总结本病例特点,并复习相关文献。结果:该例患者相继出现多囊肺、皮肤溃疡、尿崩和泌乳等典型症状。皮肤病理学检查发现真皮内密集分布的单个核细胞浸润,免疫组织化学染色CD1a(+)。随访7年,最终因心肺功能衰竭死亡。结论:LCH临床表现多种多样,确诊需要结合临床症状、病理和影像学等方法。成人LCH患者多系统重要器官受累提示预后不良。 Objective:To study the clinical and pathological features of Langerhans cell histiocytosis (LCH), and to provide the reference for its diagnosis and treatment.Methods:The manifestation of one LCH patient was retrospectively analyzed.The features of the LCH patients were explored by analyzing the results of skin biopsy, radiological test and follow-up.The associated literatures were reviewed.Results:The patient presented the typical symptoms gradually,including polycystic lung,skin ulcer,diabetes insipidus,and lactation.The skin pathological findings showed the densely distributed mononuclear cell infiltration in dermis and the immunohistological staining result showed positive CD1a. The patient was follwed up for 7 years and died of heart and lung failure. Conclusion:LHC has various manifestations and should be confirmed by clinical features,pathological features and imaging examination.The adult patients with multisystem and vital organ involvement suggest the poor prognosis.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2016年第5期985-987,I0004,F0003,共5页 Journal of Jilin University:Medicine Edition
基金 国家自然科学基金资助课题(30900591)
关键词 郎格汉斯细胞组织细胞增生症 CD1A 尿崩症 免疫组织化学 CD1a langerhans cell histiocytosis CD1a diabetes insipidus immunohistochemistry
  • 相关文献

参考文献16

  • 1Allen CE,Li L,Peters TL,et al.Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells[J].J Immunol,2010,184(8):4557-4567.
  • 2Chiong C,Jayachandra S,D Eslick G,et al.A rare case of Langerhans cell histiocytosis of the skull in an adult:a systematic review[J].Rare Tumors,2013,5(3):132-134.
  • 3Simko SJ,Garmezy B,Abhyankar H,et al.Differentiating skin-limited and multisystem Langerhans cell histiocytosis[J].J Pediatr,2014,165(5):990-996.
  • 4Abla O,Egeler RM,Weitzman S.Langerhans cell histiocytosis:Current concepts and treatments[J].Cancer Treat Rev,2010,36(4):354-359.
  • 5Senechal B,Elain G,Jeziorski E,et al.Expansion of regulatory T cells in patients with Langerhans cell histiocytosis[J].PLoS Med,2007,4(8):e253.
  • 6Chikwava KR,Hunt JL,Mantha GS,et al.Analysis of loss of heterozygosity in single-system and multisystem Langerhans'cell histiocytosis[J].Pediatr Dev Pathol,2007,10(1):18-24.
  • 7Costa CE,Szuhai K,van Eijk R,et al.No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies[J].Genes Chromosomes Cancer,2009,48(3):239-249.
  • 8Badalian-Very G,Vergilio JA,Degar BA,et al.Recurrent BRAF mutations in Langerhans cell histiocytosis[J].Blood,2010,116(11):1919-1923.
  • 9Haroche J,Charlotte F,Arnaud L,et al.High prevalence of BRAF V600Emutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses[J].Blood,2012,120(13):2700-2703.
  • 10Delprat C,Aric M.Blood spotlight on Langerhans cell histiocytosis[J].Blood,2014,124(6):867-871.

二级参考文献21

  • 1Guyot-Goubin A, Donadieu J, Barkaoui M, et al. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004 [J]. PediatrBlood Cancer, 2008, 51(1): 71-75.
  • 2Alston RD, Tatevossian RG, McNally RJ, et al. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998 [J]. Pediatr Blood Cancer, 2007, 48(5): 555-560.
  • 3Gadner H, Grois N, Arico M, et cd. A randomized trial of treat- ment for multisystem Langerhans' cell histiocytosis [J]. J Pediatr, 2001, 138(5): 728-734.
  • 4Gadner H, Grois N, Potschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification [J]. Blood, 2008, 11l(5): 2556-2562.
  • 5Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocy- tosis : results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocolstudy [J]. Cancer, 2006, 107(3): 613-619.
  • 6Derenzini E, Fina MP, Stefoni V, et aL MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis : experience on seven patients [J]. Ann Oncol, 2010, 21(6): 1173-1178.
  • 7Saven A, Foon KA, Piro LD. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans cell histiocytosis [J]. Ann Intern Med, 1994, 121(6): 430-432.
  • 8Weitzman S, Braier J, Donadieu J, et al. 2'-Chlorodeoxyadeno- sine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH) results of the LCH-S-98 protocol of the Histiocyte Society [J]. Pediatr Blood Cancer, 2009, 53(7): 1271-1276.
  • 9Bernard F, Thomas C, Bertrand Y, eta/. Multi-centre pilot study of 2-chlorodeoxyadeno- sine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with hae- matological dysfunction [J]. Eur J Cancer, 2005, 41(17): 2682- 2689.
  • 10Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease [J]. Pediatr Blood Cancer, 2014, 61(3): 479-487.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部